TG Therapeutics (NASDAQ:TGTX) Hits New 52-Week High – Should You Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX)’s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as $47.93 and last traded at $48.48, with a volume of 493673 shares changing hands. The stock had previously closed at $43.37.

Analyst Ratings Changes

Several brokerages have recently commented on TGTX. Weiss Ratings upgraded shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. Zacks Research upgraded shares of TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of TG Therapeutics in a research report on Wednesday, May 27th. Finally, Wall Street Zen cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $52.50.

TG Therapeutics Stock Up 9.2%

The company has a market capitalization of $7.25 billion, a P/E ratio of 16.57 and a beta of 1.68. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81. The firm’s fifty day moving average is $37.46 and its 200-day moving average is $32.77.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The firm had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. During the same period in the prior year, the company earned $0.03 EPS. The business’s quarterly revenue was up 69.5% compared to the same quarter last year. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 1.51 EPS for the current year.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TGTX. Danske Bank A S bought a new stake in TG Therapeutics during the 3rd quarter worth approximately $25,000. Optiver Holding B.V. grew its holdings in TG Therapeutics by 3,485.7% during the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 732 shares during the last quarter. Bessemer Group Inc. grew its holdings in TG Therapeutics by 117.1% during the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 486 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 365 shares during the last quarter. Finally, Hantz Financial Services Inc. grew its holdings in TG Therapeutics by 82.7% during the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 560 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.